Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.71 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.68 |
| ▸ | MTOR | P42345 | 1/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.66 |
| ▸ | MARK3 | P27448 | 1/20 | 0.66 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.66 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 1/20 | 0.66 |
| ▸ | NEK4 | P51957 | 1/20 | 0.66 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.66 |
| ▸ | ITK | Q08881 | 1/20 | 0.66 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25956637 | 0.81 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL24372787 | 0.81 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956628 | 0.81 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL169836 | 0.81 | IRAK4 (0.70) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL29363239 | 0.81 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL3600534 | 0.81 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL29827291 | 0.81 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956620 | 0.81 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL18427725 | 0.80 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956635 | 0.80 | IRAK4 (0.81) | IRAK4IRAK1MTORDYRK3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883409-B2 | Protection of cells from degeneration and treatment of geographic atrophy | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-01-30 | — | — | US | claimed |
| US-11739385-B2 | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-29 | — | — | US | claimed |
| US-20200206236-A1 | Protection of Cells from Degeneration and Treatment of Geographic Atrophy | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-02 | — | — | US | claimed |
| US-20200149114-A1 | DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-14 | — | — | US | claimed |
| EP-3077001-B1 | METHODS TO DISTINGUISH WALDENSTRÖM'S MACROGLOBULINEMIA FROM IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | DANA FARBER CANCER INST INC (US) | 2020-04-15 | — | — | EP | claimed |
| US-10612095-B2 | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-07 | — | — | US | claimed |
| US-10465247-B2 | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | claimed |
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-04 | — | — | US | claimed |
| US-9855273-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-02 | — | — | US | claimed |
| EP-2999470-B1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-16 | — | — | EP | claimed |
| EP-3077001-A1 | METHODS TO DISTINGUISH WALDENSTRÖM'S MACROGLOBULINEMIA FROM IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | Dana-Farber Cancer Institute, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| EP-2999470-A2 | COMBINATION THERAPY FOR MDS | Children's Hospital Medical Center (US) | 2016-03-30 | — | — | EP | claimed |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-02-11 | — | — | US | claimed |
| US-9168257-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2015-10-27 | — | — | US | claimed |
| WO-2015085075-A1 | METHODS TO DISTINGUISH WALDENSTRÖM'S MACROGLOBULINEMIA FROM IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | WO | claimed |
| WO-2014190163-A2 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-11-27 | — | — | WO | claimed |
| US-20140350070-A1 | Combination Therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2014-11-27 | — | — | US | claimed |
| US-20140249142-A1 | DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-09-04 | — | — | US | claimed |
| EP-2726634-A2 | DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA | Dana-Farber Cancer Institute, Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2013006443-A2 | DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885IRAK1 1/4885MTOR 1004/4885 |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | MCL1, IRAK4, IRAK3 | IRAK4 2/4885IRAK1 5/4885MTOR 2436/4885 |
| US-20140350070-A1 | Combination Therapy for MDS | MCL1, IRAK4, IRAK3 | IRAK4 2/4885IRAK1 5/4885MTOR 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.